Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

By

A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

By

The ability to make early adjustments to treatment has the potential to improve survival.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

By

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

By

FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

By

Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

By

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

By

A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

By

A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.

Advanced Age Should Not Prohibit ASCT for Lymphoma

Advanced Age Should Not Prohibit ASCT for Lymphoma

By

As supportive care improves, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.

Novel β-chain-targeting approach for the treatment of lymphoma [PreClinical]

1. The β-chain constant region of the T cell receptor (TCR) was targeted to specifically eliminate a population of malignant T cells. 2. Engineered chimeric antigen receptor (CAR) T cells with specificity to the β-chain constant region successfully eradicated a significant proportion of malignant T cells in mice. Evidence Rating Level: 3 (Average) Study Rundown: []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

By

The safety of breast implants has not been confirmed despite widespread use.

Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma

1. Patients with refractory diffuse large B-cell or follicular lymphoma demonstrated high rates of remission when treated with anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy. 2. Serious adverse events noticed in this cohort included cytokine release syndrome and encephalopathy. Evidence Rating Level: 3 (Average) Study Rundown: Diffuse large B-cell lymphoma and follicular lymphoma comprise []

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

By

Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

By

This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

By

Nurses' critical thinking perspective is key to recognizing and managing adverse effects in patients with lymphoma, and staying ahead of the curve in a rapidly changing clinical setting.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

By

Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

By

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

By

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs